培训课件--动脉粥样硬化病理研究进展.pptVIP

* Figure 30?Risk factor modification is a key therapeutic target in patients with and without clinically manifested atherosclerotic disease. KW: risk factor, dyslipidemia, diabetes, smoke, BP * Figure 31?In those with established AS, reducing the risk of plaque rupture can be approached via two broad therapeutic routes: by increasing plaque stability; by decreasing plaque rupture-inducing factors. KW: risk factor, plaque rupture * Figure 32?Thrombosis can be reduced by: reducing platelet adhesion (via thromboxane); inhibiting platelet aggregation (via fibrinogen and the GP IIb/IIIa rece